Gastrointestinal cancers do not get the marquee attention of lung or breast, but collectively they are one of the largest and fastest-growing fronts at ASCO. In 2026 the radar shows colorectal and gastric cancer both surging — and, in one of the most satisfying data signatures of the meeting, it captures the fingerprint of a genuinely practice-changing regimen in the rise of a single antibody.
A broad front, getting broader
Across the major GI indications, study volume is climbing on nearly every axis. Colorectal cancer reached 311 studies (up 45 in a year), gastric cancer 128 (up 24), and pancreatic and esophageal both held or grew. The one GI indication losing share of voice is hepatocellular carcinoma.
Colorectal's headline: BREAKWATER and the BRAF breakthrough
The practice-changing colorectal result at ASCO 2026 is BREAKWATER, the first-line trial of encorafenib (a BRAF inhibitor) plus cetuximab (an anti-EGFR antibody) plus chemotherapy in BRAF V600E-mutant metastatic colorectal cancer — historically one of the worst prognostic subgroups in GI oncology. In the FOLFIRI cohort, the encorafenib-cetuximab-chemo arm reached a median overall survival that was not yet reached versus 20.3 months for chemotherapy (hazard ratio 0.56), with an 18-month survival rate of 72% versus 55%. Combined with the earlier mFOLFOX6 data, BREAKWATER establishes targeted therapy as the first-line standard for BRAF V600E colorectal cancer.
You can see the breakthrough in the data
Here is where the radar earns its keep. When a regimen changes practice, the components of that regimen show up more in the research literature. Cetuximab — the anti-EGFR antibody in the BREAKWATER combination — rose 67% over two years, from 36 studies to 60.
That is the study-momentum signature of a practice change: a decades-old antibody experiencing a second act because it is now half of a breakthrough regimen. The radar surfaces this kind of second-order signal automatically — you do not need to already know which trial mattered to see its footprint in the data.
Beyond colorectal: gastric, refractory disease, and ctDNA
Gastric cancer's rise (104 → 128) is powered by HER2-directed therapy (trastuzumab, trastuzumab deruxtecan, and the HER2 bispecific zanidatamab), claudin-18.2 targeting, and immunotherapy combinations — a once-stagnant field now with multiple actionable biomarkers. In refractory colorectal cancer, the China-originated VEGFR inhibitor fruquintinib has built a durable presence (28 studies). And cutting across all GI indications is the ctDNA pivot — circulating-tumor-DNA- guided adjuvant decisions and minimal-residual-disease surveillance, the single hottest cross-cutting theme in GI oncology (covered in depth in our liquid-biopsy piece).
| GI indication | Actionable drivers | Lead agents at ASCO 2026 | Radar (2026) |
|---|---|---|---|
| Colorectal cancer | BRAF V600E, HER2, KRAS G12C, MSI/dMMR | encorafenib + cetuximab, fruquintinib | ▲ 311 |
| Pancreatic cancer | KRAS, BRCA / HRD | chemo backbones; KRAS inhibitors in trials | ▲ 152 |
| Gastric cancer | HER2, claudin-18.2, PD-L1 | trastuzumab / T-DXd, zanidatamab, zolbetuximab | ▲ 128 |
| Esophageal cancer | HER2, PD-L1 | checkpoint inhibitor + chemotherapy | ▲ 67 |
| Hepatocellular carcinoma | VEGF / IO combinations | atezolizumab + bevacizumab, durvalumab combos | ▼ 79 |
The commercialization read
For BD teams: GI oncology's growth is biomarker-led — BRAF, HER2, claudin-18.2, MSI/MMR, and KRAS G12C in colorectal each define a sub-market with room for differentiated entrants. For competitive strategy: BREAKWATER is a template — pairing a targeted backbone with an established antibody to crack a poor-prognosis subgroup is a repeatable play across GI. For investors: the cetuximab signature is a reminder that the radar surfaces practice change as it happens, often before it is reflected in guidelines or sales.
Explore the underlying data
Every number above is live and pivotable on the Knitify ASCO Radar — analyze the 7,222 studies in the ASCO 2026 program by drug, indication, sponsor, or trial-in-progress status, and compare year over year against 2025 and 2024. Filter the board to colorectal or gastric cancer to reproduce every count in this article. The radar links to each study on the official ASCO program; it does not reproduce copyrighted text.
Methodology & scope: figures in this article are structured signals the Knitify ASCO Radar derives from the publicly released ASCO 2026 scientific program (7,222 studies presented; 6,511 in 2025; 5,885 in 2024) — counting how many studies reference a given drug, indication, or modality class. They quantify research attention and momentum, not clinical efficacy or market share. Named trial results are quoted from public company press releases, the ASCO press program, and peer-reviewed journals (cited below). The radar does not reproduce any copyrighted text — it links to each study on the official ASCO program. This is editorial commentary on public data — not investment, legal, regulatory, or medical advice.